List view / Grid view
In the Phase III ACIS study, prostate cancer patients treated with a combination of Erleada® and Zytiga® plus prednisone were less likely to die than participants receiving Zytiga and prednisone.
A new oil-based oral formulation of prostate cancer drug abiraterone acetate could enable a smaller dose of the drug to be effective and reduce possible side effects, a study has shown.
The FDA has given the designation to niraparib for the treatment of gene-mutated castration-resistant prostate cancer.
The EC has granted approval to broaden the existing marketing authorisation for Zytiga to include early stage metastatic prostate cancer...
10 February 2015 | By The Institute of Cancer Research
Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said: “We’re very disappointed that Scottish men with prostate cancer will miss out on the chance to have abiraterone much earlier in their course of treatment as a result of this decision..."
15 April 2014 | By Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting…
11 October 2013 | By AstraZeneca
AstraZeneca announced that it has entered into an agreement to co-promote, an innovative oral therapy for the treatment of patients with prostate cancer...
19 August 2013 | By Johnson & Johnson
Late-stage prostate cancer treatment strengthens oncology pipeline..
11 January 2013 | By Johnson & Johnson
Janssen announced that the EC has approved an extension to the license of the oral, once-daily medication ZYTIGA®...
4 June 2011 | By Johnson & Johnson
This study represents the first randomized, double-blind, placebo controlled Phase III trial to evaluate CTCs as a potential biomarker for overall survival...
